

Effects of mitomycin C at different exposure time on the morphology of corneal endothelial cells in LASEK surgery

Kai-Yun Zhang, Ya-Ling Ma

Department of Ophthalmology, General Hospital of Ningxia Medical University, Yinchuan 750000, Ningxia Hui Autonomous Region, China

Correspondence to: Ya-Ling Ma. Department of Ophthalmology, General Hospital of Ningxia Medical University, Yinchuan 750000, Ningxia Province, China. myeye@163.com

Received: 2017-10-23 Accepted: 2018-03-29

Abstract

• **AIM:** To investigate the effects of mitomycin C (MMC) on corneal endothelial cells at different exposure time during laser-assisted subepithelial keratomileusis (LASEK).

• **METHODS:** Patients who received LASEK were included and divided into Group T1 (15s≤t≤45s) and T2 (5s<t≤70s) based on the exposure time of MMC with corneal stroma. Cell density (CD) of corneal endothelial cells in central and peripheral cornea, average cell area (ACA), area standard deviation (SD), coefficient of variation (CV) and percentage of hexagonal cells (HEX) before surgery and at 1wk, 1, 3 and 6mo after surgery were compared between and within the groups.

• **RESULTS:** A total of 196 eyes of 98 patients were included with 98 eyes in Group T1 and 98 eyes in Group T2. With the exception of peripheral ACA, central CV and HEX in Group T1 and T2, which significantly changed at 1wk after the surgery ($P<0.05$), there was no significant difference in central and peripheral parameters within both groups or between the groups ($P>0.05$).

• **CONCLUSION:** Although transient acute changes in central CV and HEX and peripheral ACA were observed, there is no significant effect on the long-term corneal health status when MMC is applied in a reasonable time range in LASEK surgery.

• **KEYWORDS:** laser-assisted subepithelial keratomileusis; mitomycin C; corneal endothelial cells

DOI:10.18240/ier.2020.02.11

Citation: Zhang KY, Ma YL. Effects of mitomycin C at different exposure time on the morphology of corneal endothelial cells in LASEK surgery. *Int Eye Res* 2020;1(2):122-127

INTRODUCTION

In recent years, there is a continuous rise in the incidence of myopia. According to statistics, the global prevalence of myopia is expected to reach 2.5 billion in 2020^[1]. Correcting myopia, especially by refractive surgery, has become the work and research focus of ophthalmologists. Laser-assisted subepithelial keratomileusis (LASEK) was first proposed by Camellin^[2] in 1999. It broadened the indication ranges of refractive surgery, avoided the interference of the negative pressure suction on the vitreous, retina^[3], and gradually became a main surgical treatment for refractive surgery. However, in eyes with a preoperative spherical equivalent (SE) greater than 12.00 D, LASEK led to a significant rate of myopic regression associated with corneal subepithelial haze (haze) development^[4].

Mitomycin C (MMC) is a commonly used anticancer drug, which can damage DNA structure and function, and inhibit DNA replication and cell proliferation. Recently, MMC has found application in preventing a few complications associated with corneal epithelium in LASEK procedure. Mirza *et al*^[5] report a case of dense and visually significant corneal haze after LASEK and was successfully treated with mitomycin-C. Mamjudar *et al*^[6] confirmed that MMC could help inhibiting haze formation and restore vision. In addition, MMC was also used to reduce the failure rate of glaucoma filtering operation, prevent recurrence of pterygium, reduce strabismus, adhesions and scar formation after lacrimal surgery, *etc.*^[7-10].

However, literature reports that inappropriate use of MMC could decrease the corneal endothelial cell count and functional failure, leading to secondary corneal edema, glaucoma, corneal perforation and other complications. Most complications of MMC were associated with its long-time use, use in high concentration and its effect on corneal limbus^[11-12]. Therefore, there are important clinical significances in investigating the safety of MMC during LASEK surgery. In this study, the effects of MMC on the corneal endothelial cells at different exposure time in LASEK surgery was evaluated.

SUBJECTS AND METHODS

Ethical Approval All patients signed informed consent, and all procedures performed in studies involving human

participants were in accordance with the ethical standards of the General Hospital of Ningxia Medical University ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Inclusion and Exclusion Criteria Patients who had the subjective will of undergoing LASEK surgery from October 2016 to March 2017 in our hospital were included in this study. For every enrolled patient, the refractive error was required to have been stable for at least 2y and the contact lens wearing time was less than 5y with 2wk of no lens-wearing before the surgery. In addition, the medical examination results of some patients had met the criteria of LASEK, but their first choice was LASIK and existed at least one of these followings: a) Relatively high degree of myopia with thin cornea; b) The occupations with high forward risk of cornea flap, such as armed police, boxing, and athletes, *etc*; c) Special anatomic conditions such as small palpebral fissure or deep socket. These patients agreed to undergo LASEK after comprehending informed consent and were also included in our study. Exclusion Criteria: Patients with preoperative endothelial cells density (ECD) $<2000/\text{mm}^2$, or the surgery history which affected the corneal endothelial cells such as glaucoma, cataract, and corneal surgery were excluded. All patients had a detailed understanding of the surgical approach, advantages and disadvantages, expected effects, risks and possible complications.

Preoperative Examination All the study patients underwent preoperative examinations, which included uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), dominant eye, autorefraction, anterior segment examination, fundus examination, intraocular pressure, corneal thickness, axial length, corneal topography and corneal endothelial cell count. The fundus examination was taken by direct ophthalmoscope and three-mirror contact lens after mydriasis.

Surgical Methods Conjunctival sac surface anesthesia was performed with 4% oxybuprocaine, and the epithelium was trephined. A marker was placed on the cornea and centered on the pupil. Then 20% alcohol (0.1 mL) was instilled inside the trephine and left for 15-25s. A cotton swab was used to absorb the alcohol and balanced salt solution (BSS) was copiously instilled to rinse the ocular surface. An intact corneal flap with the diameter of 8 mm and the above as the fundus was separated using the epikeratome from 6 o'clock position and the pedicle was rolled up and accumulated at 12 o'clock position. The laser ablation was performed according to the planned corrected degree after the laser was adjusted and aligned to the pupil center. A new prepared MMC cotton sheet of 6 mm diameter was used to cover the laser ablation area. The operative area was then washed with 20 mL BSS solution. The epithelium flap was relocated and Johnson clear corneal

contact lens with the degree of -1.0 D and the diameter of 14.0 mm was placed.

Method of MMC Usage and Categorizing the Patients Ten minutes before the beginning of surgery, a sterile dilute solution of MMC 0.02% was prepared by mixing MMC for injection (2 mg, Zhejiang Haizheng pharmaceutical production) with 10 mL saline. SS-96A Kang, a medical sponge was cut into round sponge with 6 mm diameter and 1 mm thickness under the asepsis procedure and placed in the prepared MMC 0.02% solution to completely soak the solution. The sponge infiltrated with MMC 0.02% was picked up by clamps, with no drop of liquid, and is placed on the central of stroma in cornea ablation area, and the exposure time was according to the diopter: 65-70s for spherical equivalent refraction ≥ 8.00 D, 50-60 s for spherical equivalent refraction was -6.00 D to -7.75 D, 35-45s for spherical equivalent refraction was -3.75 D to -5.75 D, and 15-30s for spherical equivalent refraction ≤ -3.50 D. The patients were classified into two groups, T1 ($15\text{s} \leq t \leq 45\text{s}$) and T2 ($45\text{s} < t \leq 70\text{s}$), based on the time of treatment with MMC 0.02% in the surgery.

Postoperative Management After surgery, anti-inflammatory eye drops (diclofenac sodium; 4 times a day), artificial tears (0.1% sodium hyaluronate eye drops; 5 times a day), and an antibiotic (levofloxacin eye drops; 5 times a day) were administered. The corneal contact lenses were taken out after corneal epithelial healing was over and a steroid (fluorometholone eye drops; 6 times a day) was administered from the fifth day after surgery. The dose of the steroid eye drops was tapered to 1 time per week until withdrawal. Slit-lamp examination was performed a day after surgery to check whether the corneal contact lens were in the position and the healing of corneal epithelium. The patients were followed-up at 1wk, 1, 3 and 6mo after surgery. During the follow-up, visual acuity, intraocular pressure, refraction and corneal topography were examined and the healing of corneal epithelium and corneal endothelial density were observed.

Evaluation Criteria 1) Safety criteria: Intraoperative and postoperative complications including ocular irritation symptoms, healing delay and occurrence of haze^[13]; 2) Corneal endothelial cell criteria: cell density (CD) of corneal endothelial cells in central and peripheral cornea, average cell area (ACA), area standard deviation (SD), coefficient of variation (CV, standard deviation/average cell area) and percentage of hexagonal cells (HEX) before surgery and 1wk, 1, 3 and 6mo after surgery. The 4 sites examined were: The site above the eye (12 o'clock position), the site below the eye (6 o'clock position), the site on the nasal side (2 o'clock position of the right eye and 10 o'clock position of the left eye) and the site on the temporal side (10 o'clock position of the right eye and 2 o'clock position of the left eye) around the central site of the cornea. All the

Table 1 Preoperative and postoperative endothelial cell density with different exposure times mean±SD (cells/mm²)

Groups	Sites	Preoperative	Postoperative			
			1wk	1mo	3mo	6mo
Group T1 (n=98)	Central	2651.14±206.54 (2444.60, 2857.68)	2619.03±183.83 (2435.20, 2802.86)	2650.54±227.17 (2423.37, 2877.71)	2608.81±229.11 (2379.70, 2837.92)	2632.50±244.91 (2387.59, 2877.41)
	Peripheral	2632.14±238.78 (2393.36, 2870.92)	2658.14±234.98 (2423.16, 2892.32)	2661.43±206.16 (2455.27, 2867.59)	2614.77±223.88 (2380.89, 2838.65)	2628.50±234.61 (2393.89, 2863.11)
Group T2 (n=98)	Central	2663.12±210.03 (2453.09, 2873.15)	2643.47±168.56 (2474.91, 2812.03)	2630.78±257.06 (2373.72, 2887.84)	2602.44±258.22 (2344.22, 2860.66)	2592.37±255.75 (2336.62, 2848.12)
	Peripheral	2708.76±270.63 (2438.13, 2979.39)	2634.76±242.56 (2392.20, 2877.32)	2681.61±281.55 (2400.06, 2963.16)	2661.40±302.22 (2359.18, 2963.62)	2690.38±244.93 (2445.45, 2935.31)

Table 2 Preoperative and postoperative average endothelial cell area with different exposure times mean±SD (cells/mm²)

Groups	Sites	Preoperative	Postoperative			
			1wk	1mo	3mo	6mo
Group T1 (n=98)	Central	375.45±40.19 (335.26, 415.64)	383.80±59.73 (324.07, 443.53)	377.70±40.78 (336.92, 418.48)	387.40±61.16 (326.24, 448.56)	378.61±63.89 (314.72, 442.50)
	Peripheral	383.92±37.45 (346.47, 421.37)	397.60±42.22 ^a (355.38, 439.82)	378.20±48.24 (329.96, 426.44)	391.06±61.30 (329.76, 452.36)	390.73±65.02 (325.71, 455.75)
Group T2 (n=98)	Central	382.17±42.44 (339.73, 424.61)	377.39±42.81 (334.58, 420.20)	381.74±42.04 (339.70, 423.78)	372.44±49.88 (322.56, 422.32)	389.61±55.79 (333.82, 445.40)
	Peripheral	371.41±42.41 (329.00, 413.82)	395.61±48.97 ^b (346.64, 444.58)	390.94±70.33 (320.61, 461.27)	389.78±45.57 (344.21, 435.35)	367.80±51.46 (316.34, 419.26)

^aP=0.035; ^bP=0.015.

peripheral 4 sites were 3 mm away from the central site of the cornea. All these sites were measured three times and a clear image was obtained according to the requirements. All the examinations were performed by the same examiner.

Statistical Analysis Data were represented as means±SD and the statistical analyses have been carried out with SPSS 19.0 software for Windows (SPSS Inc., Chicago, IL, USA). The comparison among groups and comparison of the preoperative and postoperative corneal endothelial cell parameters at different exposure time points were performed by using the repeated measures analysis of variance. *P*<0.05 was considered statistically significant.

RESULTS

Summary of Patient Data A total of 98 patients (196 eyes) including 50 males and 48 females aged from 18 to 37 years old were included in our study. The participants were divided into Group T1 (98 eyes) and Group T2 (98 eyes). The age and gender between groups were comparable. The refractive error of all patients was stable for more than 2y. The spherical equivalent refraction was -5.81±1.54 D (-1.50D to -9.25 D). The astigmatic degree was -1.25±1.25 D (0 to -2.50 D), and the corrected visual acuity was 0.9±0.1 (0.8-1.0). The time for contact lens wearing was less than 5y, and time for removing the lens was more than 2wk. The ablation diameters were 6.5 mm in 180 eyes and 6.0 mm in 18 eyes respectively.

Complications The surgical procedure was successful in all study patients with no complications during the surgery. Mild-

to-moderate ocular irritation symptom was observed in 13 eyes 1d after the surgery, but the symptoms relieved in 1-2d. Delayed corneal epithelial healing was observed in 4 eyes. They were treated by delaying the removal of corneal contact lens for 2d. According to the Fantes method, the haze was in level 0.5 and level 1 at 1mo after surgery, which recovered 6mo after surgery.

Cell Density of Corneal Endothelial Cells The preoperative and postoperative CD values in Group T1 and T2 at different action time points are shown in Table 1. The central site: Test within group *F*=1.533, *P*=0.196 and test between groups *F*=0.023, *P*=0.881. The peripheral sites: Test within group *F*=0.644, *P*=0.624, and test between groups *F*=0.670, *P*=0.415. The results indicated that there was no significant difference of the central and peripheral CD values within a group or between groups at each action time point (*P*>0.05).

Average Cell Area in Corneal Endothelial Cells The preoperative and postoperative ACA values in Group T1 and T2 at different action time points are shown in Table 2. The central site: Test within group *F*=0.146, *P*=0.949 and test between groups *F*=0.00, *P*=0.991. The peripheral sites: Test within group *F*=1.48, *P*=0.216 and test between groups *F*=0.874, *P*=0.352. The crossover effects between inter-group and within-group had significant difference (*F*=4.082, *P*<0.05). The peripheral ACA values had significant difference between preoperation and 1wk postoperation in GroupT1 (*P*=0.035) and T2 (*P*=0.015). The results indicated that except

Table 3 Preoperative and postoperative coefficient of variation of corneal endothelial cells with different exposure times mean±SD (cells/mm²)

Groups	Site	Preoperative	Postoperative			
			1wk	1mo	3mo	6mo
Group T1 (n=98)	central	35.12±7.06 (28.06, 42.18)	38.95±6.56 ^a (32.39, 45.51)	36.16±5.76 (30.40, 41.92)	36.64±6.40 (30.24, 43.04)	36.86±5.63 (31.23, 42.49)
	peripheral	36.23±6.94 (29.29, 43.17)	36.88±6.32 (30.56, 43.20)	37.22±6.71 (30.51, 43.93)	37.84±7.63 (30.21, 45.47)	36.31±6.09 (30.22, 42.40)
Group T2 (n=98)	central	34.68±5.67 (29.01, 40.35)	37.86±4.59 ^b (33.27, 42.45)	35.04±6.06 (28.98, 41.10)	36.94±6.95 (29.99, 43.89)	36.57±6.51 (30.06, 43.08)
	peripheral	36.29±4.49 (31.80, 40.78)	39.72±6.82 (32.90, 46.54)	38.08±5.23 (32.85, 43.31)	37.71±6.46 (31.25, 44.17)	37.23±5.57 (31.66, 42.80)

^aP=0.012, ^bP=0.016.

Table 4 Preoperative and postoperative percentage of hexagon of cells in corneal endothelium with different exposure times mean±SD, %

Groups	Site	Preoperative	Postoperative			
			1wk	1mo	3mo	6mo
Group T1 (n=98)	Central	54.15±12.20 (41.95, 66.35)	49.35±11.13 ^a (38.22, 60.48)	51.59±12.66 (38.93, 64.25)	49.19±13.11 (36.08, 62.3)	50.53±11.90 (38.63, 62.43)
	Peripheral	53.43±12.01 (41.42, 65.44)	54.88±13.31 (41.57, 68.19)	51.26±12.26 (39.00, 63.52)	52.24±12.45 (39.79, 64.69)	52.46±12.31 (40.15, 64.77)
Group T2 (n=98)	Central	55.79±13.10 (42.69, 68.89)	48.43±10.93 ^b (37.50, 59.36)	51.07±12.64 (38.43, 63.71)	49.14±14.88 (34.26, 64.02)	54.10±11.10 (43.00, 65.20)
	Peripheral	53.59±11.83 (41.76, 65.42)	52.10±11.59 (40.51, 63.69)	51.62±12.47 (39.15, 64.09)	50.14±12.88 (37.26, 63.02)	51.55±10.90 (40.65, 62.45)

^aP=0.007, ^bP=0.017.

the peripheral ACA values increased at 1wk after surgery, there was no significant difference of the central and peripheral ACA values within a group or between groups at other action time points.

Coefficient of Variation of Corneal Endothelial Cells The preoperative and postoperative CV values in Group T1 and T2 at different time points are shown in Table 3. The central site: Test within group $F=2.281$, $P=0.065$ and test between groups $F=1.093$, $P=0.302$. The peripheral sites: Test within group $F=1.690$, $P=0.159$ and test between groups $F=1.008$, $P=0.318$. The significant difference had been showed in crossover effects between inter-group and within-group ($F=4.136$, $P<0.05$). The central CV values had significant difference between preoperation and 1wk postoperation in Group T1 ($P=0.012$) and T2 ($P=0.016$). The results indicated that there was no significant difference of the central and peripheral CV values within a group or between groups at each action time points, except the central CV values increased at 1wk after surgery.

Percentage of Hexagon of Cells in Corneal Endothelium The preoperative and postoperative HEX values in Group T1 and T2 at different action time points are shown in Table 4. The central site: Test within group $F=0.058$, $P=0.811$ and test between groups $F=0.693$, $P=0.407$. The peripheral sites: Test within group $F=2.250$, $P=0.081$ and test between groups $F=2.04$, $P=0.157$. The crossover effects between inter-group

and within-group had significant difference ($F=4.165$, $P<0.05$). The peripheral ACA values had significant difference between preoperation and 1wk postoperation in Group T1 ($P=0.035$) and T2 ($P=0.015$).

The results indicated that except for the central HEX values which increased 1wk after surgery in group T1 ($P=0.007$) and T2 ($P=0.017$), there was no significant difference of the central and peripheral HEX values within a group or between groups at the other action time points.

Standard Deviation of Cell Area in Corneal Endothelial Cells The preoperative and postoperative SD values in Group T1 and T2 at different action time points are shown in Table 5. The central site: Test within group $F=1.481$, $P=0.212$ and test between groups $F=0.006$, $P=0.937$. The peripheral sites: Test within group $F=1.524$, $P=0.204$ and test between groups $F=0.131$, $P=0.719$. The results indicated that there was no significant difference of the central and peripheral SD values within a group or between groups at each action time point ($P>0.05$).

DISCUSSION

LASEK surgery is mainly carried out in patients with high myopia and relatively thin cornea^[14]. However, it can cause a few complications, especially haze. In the past 10y, researchers found that MMC could reduce the incidence of haze and prevent refractive regression^[15-16]. MMC is a cytotoxic drug

Table 5 Preoperative and postoperative standard deviation of endothelial cell area with different exposure times mean±SD

Groups	Site	Preoperative	Postoperative			
			1wk	1mo	3mo	6mo
Group T1 (n=98)	central	134.65±21.78 (112.87, 156.43)	137.18±28.14 (109.04, 165.32)	136.03±25.44 (110.59, 161.47)	141.08±30.12 (110.96, 171.20)	140.42±24.30 (116.12, 164.72)
	peripheral	139.11±32.58 (106.53, 171.69)	138.96±27.14 (111.82, 166.10)	139.22±25.19 (114.03, 164.41)	146.98±32.88 (114.10, 179.86)	141.83±33.52 (108.31, 175.35)
Group T2 (n=98)	central	132.62±22.10 (110.52, 154.75)	138.83±16.82 (122.01, 155.65)	142.76±26.41 (116.35, 169.17)	132.55±21.88 (110.67, 154.43)	143.93±30.72 (113.21, 174.65)
	peripheral	138.34±24.10 (114.24, 162.44)	148.51±25.94 (122.57, 174.45)	143.27±22.98 (120.29, 166.25)	147.12±31.63 (115.49, 178.75)	136.38±25.48 (110.90, 161.86)

that can inhibit the growth of many types of cells. A previous report suggested that the toxicity of MMC on fibroblasts increased with the prolongation of time^[17]. Therefore, it was important to study the influence of MMC on corneal cells including corneal endothelial cells, which keep the relative dehydration state of cornea to maintain the transparency relying their aqueous barrier and pump function. In this study, we compared the effects of MMC on corneal endothelial cell parameters at different application times to provide a reference for the rational use of MMC.

In this study, patients were grouped according to the contact time of MMC with the corneal stroma, and corneal endothelial cell parameters were measured. The patients were followed up for 1wk, 1, 3 and 6mo after the surgery. The results showed that CV and HEX of central corneal endothelial cells significantly changed at postoperative 1wk compared with preoperative parameters, which have no difference at postoperative 1mo, suggesting that different action time of MMC could cause transient changes in central and peripheral corneal endothelial cells. This result is similar to the one previously reported by Zhou *et al*^[18]. The changes of CV and HEX in a short time period after LASEK surgery were collectively referred to as "acute changes"^[19]. It was possibly a kind of reflex stress that chemicals damage corneal stroma layer, which did not significantly affect the barrier and liquid pump function of endothelial cells. Similarly, the acute changes can return to normal, confirming that the recommended MMC action time was reasonable. It is suggested that the MMC should be used cautiously during the surgical process, and its contact time with corneal stroma should be controlled as far as possible. MMC should be used in the central cornea, avoiding contact with the corneal limbus, and reducing the impact on the corneal limbal stem cells.

In this study, it was confirmed that there were no significant differences in other corneal endothelial cell indices in other action time points between the two groups, which could eventually return to the preoperative levels. Among all patients, the MMC maximum use time was 70 s in one patient whose binocular refractive degree both were -7.75DS and

-1.75DC×180A. Mild irritation symptoms were observed on the first day after the surgery, which disappeared 5d later with a transparent cornea and well-healed epithelium. In corneal endothelial cells, CD: 2713.80 cells/mm², ACA: 368.5 mm², CV: 35.9%, HEX: 53%, and SD: 132.2. No other complications were observed. It was speculated that Descemet's membrane could effectively reduce the adverse effects of long time MMC on corneal endothelium. Similarly, the results of previous studies by de Benito-Llopis L *et al*^[20] and Zare M *et al*^[21] showed that CD of postoperative central point did not significantly change after MMC treatment. Corneal endothelial cell density is an important index to detect the functional status of corneal endothelial cells and the quantity of corneal functional reserve. The difference might be due to the measuring range, position and counting method of the corneal endothelial cell detecting instrument.

In addition, there was a transient significant increase in ACA of peripheral corneal endothelial cells at 1wk and at 1mo after surgery, the preoperative level was restored. The reason might be that the central corneal endothelium was relatively more affected than peripheral endothelium after the laser ablation area was soaked with 6 mm diameter MMC cotton piece during LASEK surgery, causing the peripheral endothelial cells to migrate towards the center in the form of transient expansion, leading to an increase in the average area of peripheral corneal endothelial cells. However, the number of cases included in this study was relatively small. Corneal endothelial cell monitoring was not performed within 1wk after surgery, and the follow-up time span was long. Due to these limitations, additional studies are required to confirm the outcomes of this study.

To sum up, during LASEK surgery, a single-use of MMC in a reasonable time range does not significantly impact the long-term corneal health status, although transient acute changes in central CV, HEX, and peripheral ACA were observed for a short duration of time after the surgery.

ACKNOWLEDGEMENTS

Conflicts of Interest: Zhang KY, None; Ma YL, None.

Peer Review File: Available at: http://ier.ijo.cn/gjykier/ch/reader/download_attache_file.aspx?seq_id=20210325152737001&flag=1&journal_id=gjykier&year_id=2020&issue=2

REFERENCES

- 1 Morgan IG, Ohno-Matsui K, Saw SM. Myopia. *Lancet* 2012; 379(9827):1739-1748.
- 2 Camellin M. Laser epithelial keratomileusis for myopia. *J Refract Surg* 2003;19(6):666-670.
3. Yee RW, Yee SB. Update on laser subepithelial keratectomy (LASEK). *Curr Opin Ophthalmol* 2004;15(4):333-341.
4. Aydin B, Cagil N, Erdoğan S, Erdurmus M, Hasiripi H. Effectiveness of laser-assisted subepithelial keratectomy without mitomycin-C for the treatment of high myopia. *J Cataract Refract Surg* 2008;34(8):1280-1287.
- 5 Mirza MA, Qazi MA, Pepose JS. Treatment of dense subepithelial corneal haze after laser-assisted subepithelial keratectomy. *J Cataract Refract Surg* 2004;30(3):709-714.
- 6 Majmudar PA, Forstot SL, Dennis RF, Nirankari VS, Damiano RE, Brenart R, Epstein RJ. Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. *Ophthalmology* 2000;107(1):89-94.
- 7 Edward D, Al Habash A, Aljasim L, Owaidhah O. A review of the efficacy of mitomycin C in glaucoma filtration surgery. *Clin Ophthalmol* 2015:1945.
- 8 Martins TG, Costa AL, Alves MR, Chammas R, Schor P. Mitomycin C in pterygium treatment. *Int J Ophthalmol* 2016;9(3):465-468.
- 9 Choi S, Cheong Y, Shin JH, Kim KA, Bang JB, Jin KH, Park HK. Short-term response of mitomycin C on the human rectus muscle following strabismus surgery: histological, ultrastructural, and biomechanical evaluation. *Microsc Microanal* 2013;19(1):227-232.
- 10 Feng YF, Yu JG, Shi JL, Huang JH, Sun YL, Zhao YN. A meta-analysis of primary external dacryocystorhinostomy with and without mitomycin C. *Ophthalmic Epidemiol* 2012;19(6):364-370.
- 11 Rubinfeld RS, Pfister RR, Stein RM, Foster CS, Martin NF, Stoleru S, Talley AR, Speaker MG. Serious complications of topical mitomycin-C after pterygium surgery. *Ophthalmology* 1992;99(11):1647-1654.
- 12 Pfister RR. Permanent corneal edema resulting from the treatment of PTK corneal haze with mitomycin: a case report. *Cornea* 2004;23(7):744-747.
13. Fantes FE, Hanna KD, Waring GO 3rd, Pouliquen Y, Thompson KP, Savoldelli M. Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. *Arch Ophthalmol* 1990;108(5):665-675.
- 14 Virasch VV, Majmudar PA, Epstein RJ, Vaidya NS, Dennis RF. Reduced application time for prophylactic mitomycin C in photorefractive keratectomy. *Ophthalmology* 2010;117(5):885-889.
- 15 Shi JJ, Yuan YX, Zhao SX, Xu JL, Guo M. Effects of different mitomycin C concentrations on laser-assisted subepithelial keratectomy. *Exp Ther Med* 2014;7(6):1591-1594.
- 16 Sia RK, Ryan DS, Edwards JD, Stutzman RD, Bower KS. The US Army Surface Ablation Study: comparison of PRK, MMC-PRK, and LASEK in moderate to high myopia. *J Refract Surg* 2014;30(4):256-264.
- 17 Khaw PT, Sherwood MB, MacKay SL, Rossi MJ, Schultz G. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. *Arch Ophthalmol* 1992;110(8):1150-1154.
- 18 Zhou J, Lu S, Dai J, Yu Z, Zhou H, Zhou X. Short-term corneal endothelial changes after laser-assisted subepithelial keratectomy. *J Int Med Res* 2010;38(4):1484-1490.
- 19 Mardelli PG, Piebenga LW, Matta CS, Hyde LL, Gira J. Corneal endothelial status 12 to 55 months after excimer laser photorefractive keratectomy. *Ophthalmology* 1995;102(4):544-549; discussion 548-9.
- 20 de Benito-Llopis L, Teus MA, Ortega M. Effect of mitomycin-C on the corneal endothelium during excimer laser surface ablation. *J Cataract Refract Surg* 2007;33(6):1009-1013.
- 21 Zare M, Jafarinasab MR, Feizi S, Zamani M. The effect of mitomycin-C on corneal endothelial cells after photorefractive keratectomy. *J Ophthalmic Vis Res* 2011;6(1):8-12.